Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments

Japanese Journal of Infectious Diseases

Volumn 63, Issue 1, 2010, Pages 8-15

  Tamura, Shin Ichi ^a   Hasegawa, Hideki ^a   Kurata, Takeshi ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN B SUBUNIT; HEMAGGLUTININ; INFLUENZA VACCINE;

ANTIBODY RESPONSE; BAGG ALBINO MOUSE; BODY WEIGHT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; HUMORAL IMMUNITY; HYPOTHESIS; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A H1N1; INNATE IMMUNITY; NONHUMAN; REVIEW; TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; TRANSLATIONAL RESEARCH; VACCINES, INACTIVATED;

EID: 76649094925     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Lamb, R.A. and Krug, R.M. (1996): Orthomyxoviridae: the viruses and their replication. p. 1353-1395. In Fields, B.N., Knipe, D.N., et al. (eds), Virology. Lippincott-Raven Publishers, Philadelphia.
2. Murphy, B.R. and Webster, R.G. (1996): Orthomyxoviruses. p. 1397-1445. In Fields, B.N., Knipe, D.N., et al. (eds), Virology. Lippincott-Raven Publishers, Philadelphia.
3. Murphy, B.R. and Clements, M.L. (1989): The systemic and mucosal immune response of humans to influenza A virus. Curr. Top. Microbiol. Immunol., 146, 107-116.
4. Murphy, B.R. (1994): Mucosal immunity to viruses. p. 333-343. In Ogra, P.L., Lamm, M.E., McGhee, J.R., et al. (eds), Handbook of Mucosal Immunology. Academic Press, San Diego.
5. McMichael, A. (1994): Cytotoxic T lymphocytes specific for influenza virus. Curr. Top. Microbiol. Immunol., 189, 75-91.
6. Couch, R.B. and Kasel, J.A. (1983): Immunity to influenza in man. Ann. Rev. Microbiol., 37, 529-549.
7. Ada, G.L. and Jones, P.D. (1986): The immune response to influenza infection. Curr. Top. Microbiol. Immunol., 128, 1-54.
8. Tamura, S.-I. and Kurata, T. (2004): Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn. J. Infect. Dis., 57, 236-247.
9. Tamura, S.-I., Tanimoto, T. and Kurata, T. (2005): Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis., 58, 195-207.
10. Fassler, R., Martin, K., Forsberg, E., et al. (1995): Knockout mice: how to make them and why. The immunological approach. Int. Arch. Allergy Immunol., 106, 323-334.
11. Naito, T., Suda, T., Suzuli, K., et al. (2008): Lung dendritic cells have a potent capability to induce production to immunoglobulin A. Am. J. Respir. Cell. Mol. Biol., 38, 161-167.
12. Tezuka, H., Abe, Y., Iwata, M., et al. (2007): Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature, 448, 929-933.
13. Maassab, H.F. (1967): Adaptation and growth characteristics of influenza virus at 25°C. Nature (London), 213, 612-614.
14. Centers for Disease, Control and Prevention (2009): Recommendations of the ACIP, 2009: Prevention and control of seasonal influenza with vaccines. Morbid. Mortal. Wkly. Rep., 58 (PR-08), 1-52.
15. Keitel, W.A. and Piedra, P.A. (1998): Chapter 28. Live cold-adapted, reassortant influenza vaccines (USA). p. 373-390. In Nicholson, K.G., Webster, R.G. and Hay, A.J. (eds), Textbook of Influenza. Blackwell Science.
16. Black, R.A., Rota, P.A., Gorodkova, N., et al. (1993): Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol., 74, 143-146.
17. Chen, Z., Sahashi, Y., Matsuo, K., et al. (1998): Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine, 16, 1544-1549.
18. Chen, Z., Kadowaki, S., Hagiwara, Y., et al. (2001): Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine, 19, 1446-1455.
19. Chen, Z., Kurata, T. and Tamura, S.-I. (2000): Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins. Jpn. J. Infect. Dis., 53, 219-228.
20. Ulmer, J.B., Donnelly, J.J., Parker, S.E., et al. (1993): Heterogous protection against influenza by injection of DNA encoding a viral protein. Science, 259, 1745-1749.
21. Tamura, S.-I., Samegai, Y., Kurata, H., et al. (1988): Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine, 6, 409-413.
22. Tamura, S.-I., Yamanaka, A., Shimohara, M., et al. (1994): Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine, 12, 419-426.
23. Tamura, S.-I., Asanuma, H., Ito, Y., et al. (1992): Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur. J. Immunol., 22, 477-481.
24. Tamura, S.-I., Ito, Y., Asanuma, H., et al. (1992): Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol., 149, 981-988.
25. Durrer, P., Gluck, U., Spyr, C., et al. (2003): Mucosal antibody responses induced with a nasal virosome-based influenza vaccine. Vaccine, 21, 4328-4334.
26. Mutsch, M., Zhou, W., Rhodes, P., et al. (2004): Use of the inactivated intranasal influenza vaccines and the risk of Bell's palsy in Switzerland. N. Engl. J. Med., 350, 896-903.
27. Watanabe, I., Hagiwara, Y., Yoshikawa, T., et al. (2002): Immune responses against nasal adjuvant (CT112K)-combined influenza vaccine. Vaccine, 20, 3443-3455.
28. Ito, R., Yoshikawa, T., Ozaki, Y., et al. (2003): Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine, 21, 2362-2371.
29. Hashigucci, K., Ogawa, H., Ishidate, T., et al. (1996): Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine, 14, 113-119.
30. Tamura, S.-I. and Kurata, T. (1997): Intranasal immunization for human application. Mucosal Immunol. Update, 5, 8-10.
31. Hashigucci, K., Tamura, S.-I., Kurata, T., et al. (1997): Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers. J. Jpn. Assoc. Infect. Dis., 71, 153-161.
32. Hirabayashi, Y., Tamura, S.-I., Funato, H., et al. (1991): H-2-unrestricted adjuvant effect of cholera toxin B subunit on murine antibody responses to influenza virus haemagglutinin. Immunology, 72, 320-335.
33. Takada, A., Matsushita, S., Ninomiya, A., et al. (2003): Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine, 21, 3212-3218.
34. Yoshikawa, T., Suzuki, Y., Nomoto, A., et al. (2002): Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. Vaccine, 21, 60-66.
35. Lund, J.M., Alexopoulou, L., Sato, A., et al. (2004): Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA, 101, 5598-5603.
36. Diebold, S.S., Kaisho, T., Hemmi, H., et al. (2004): Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 303, 1529-1531.
37. Kang, S.M., Guo, L., Yao, Q., et al. (2004): Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J. Virol., 78, 9624-9632.
38. Kuno-Sakai, H., Kimura, M., Ohta, K., et al. (1994): Developments in mucosal influenza virus vaccines. Vaccine, 12, 1303-1310.
39. Muszkat, M., Ben Yehuda, A., Schein, M.H., et al. (2000): Local and systemic immune response in community-dwelling elderly after intra-nasal or intramuscular immunization with inactivated influenza vaccine. J. Med. Virol., 61, 100-106.
40. Greenbaum, E., Furst, A., Kiderman, A., et al. (2002): Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine, 20, 7-8.
41. Muszkat, M., Greenbaum, E., Ben-Yehuda, A., et al. (2003): Local and systemic immune responses in nursing-home elderly following intra-nasal or intramuscular immunization with inactivated influenza vaccine. Vaccine, 21, 1180-1186.
42. Matsuo, K., Yoshikawa, T., Asanuma, H., et al. (2000): Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). Vaccine, 18, 2713-2722.
43. Asanuma, H., Thompson, A.H., Iwasaki, T., et al. (1997): Isolation and characterization of mouse nasal-associated lymphoid tissue. J. Immunol. Methods, 202, 123-131.
44. Ichinohe, T., Iwasaki, A. and Hasegawa, H. (2008): Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Rev. Vaccines, 7, 1435-1445.
45. Ichinohe, T., Lee, H.K., Ogura, Y., et al. (2009): Inflammasome recognition of influenza virus is essential for adaptive immune responses. J. Exp. Med., 206, 79-87.
46. Mak, N.K., Schiltknecht, E. and Ada, G.L. (1983): Protection of mice against influenza virus infection: enhancement of nonspecific cellular responses by Corynebacterium parvum. Cell. Immunol., 78, 314-325.
47. Abe, T., Takahashi, H., Hamazaki, H., et al. (2003): Baculovirus induces an innate response and confers protection from lethal influenza virus infection in mice. J. Virol., 171, 1133-1139.
48. Hemmi, H., Takeuchi, O., Kawai, T., et al. (2000): A Toll-like receptor recognizes bacterial DNA. Nature, 408, 656-660.
49. Alexopoulou, L., Holt, A.C., Medzhitov, R., et al. (2001): Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3. Nature, 423, 732-738.
50. Akira, S., Takeda, K. and Kaisho, T. (2001): Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol., 2, 675-680.
51. Krieg, A.M., Matson, A., Yi, S., et al. (1995): CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 375, 546-549.
52. Tokunaga, T., Yamamoto, T. and Yamamoto, S. (1999): How BCG led to the discovery of immunostimulatory DNA. Jpn. J. Infect. Dis., 52, 1-11.
53. Moldoveanu, Z., Love-Homan, L., Huang, W.Q., et al. (1998): CpG DNA, a novel immune enhancer for systemic and mucosa immunization with influenza virus. Vaccine, 16, 1216-1224.
54. Kaisho, T. and Akira, S. (2002): Toll-like receptors as adjuvant receptors. Biochem. Biophys. Acta, 1589, 1-13.
55. Abe, T., Hemmi, H., Miyamoto, H., et al. (2005): Involvement of Toll-like receptor 9 signaling pathway in the induction of innate immunity by Baculovirus. J. Virol., 79, 2847-2858.
56. Ichinohe, T., Watanabe, I., Ito, S., et al. (2005): Synthetic double-stranded RNA Poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol., 79, 2910-2919.
57. Ichinohe, T., Tamura, S.-I., Kawaguchi, A., et al. (2007): Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated vaccine. J. Infect. Dis., 196, 1313-1320.
58. Yang, Z., Stratton, C., Francis, P.J., et al. (2008): Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N. Engl. J. Med., 359, 1456-1463.